Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Autonomic Failure Clear all
Terminated Phase 3 Interventional Results available

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

NCT01927055
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
New York, New York • Charlotte, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 20, 2026, 5:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Autonomic Failure Patients for RNA Blood Sampling

NCT00742586
View directory record Official record
Conditions
Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Plus Syndromes
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
50 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 20, 2026, 5:40 AM EDT
Completed No phase listed Observational

Synuclein-One Study

NCT04700722
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure
Interventions
Skin Biopsy
Diagnostic Test
Lead sponsor
CND Life Sciences
Other
Eligibility
40 Years to 99 Years
Enrollment
428 participants
Timeline
2021 – 2023
U.S. locations
23
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Sep 20, 2026, 5:40 AM EDT
Recruiting Phase 1 Interventional

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

NCT02897063
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Orthostatic Hypotension
Interventions
Droxidopa, Midodrine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 20, 2026, 5:40 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy

NCT01522235
View directory record Official record
Conditions
Autoimmune Autonomic Ganglionopathy (AAG)
Interventions
Double blinded IVIg, Double blinded Placebo, Single Blinded IVIg
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 20, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Autonomic Nervous System and Obesity

NCT00179023
View directory record Official record
Conditions
OBESITY, HYPERTENSION, PURE AUTONOMIC FAILURE, SHY-DRAGER SYNDROME
Interventions
Trimethaphan, Pseudoephedrine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 20, 2026, 5:40 AM EDT
Terminated No phase listed Observational

Magnetic Resonance Spectroscopy in Autonomic Failure

NCT01607268
View directory record Official record
Conditions
Pure Autonomic Failure, Multiple System Atrophy
Interventions
Magnetic Resonance Spectroscopy Imaging
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 20, 2026, 5:40 AM EDT
Completed Early Phase 1 Interventional Results available

Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients

NCT04620382
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease
Interventions
Midodrine, Placebo pill, Abdominal compression, sham compression
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 20, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

NCT00782340
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Placebo, Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 20, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitric Oxide and the Autonomic Nervous System

NCT00178919
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure
Interventions
L-NMMA, Trimethaphan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 20, 2026, 5:40 AM EDT
Terminated No phase listed Observational

Evaluation of Primary Chronic Autonomic Failure

NCT00059033
View directory record Official record
Conditions
Autonomic Nervous System Diseases
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 20, 2026, 5:40 AM EDT
Completed No phase listed Observational

Biomarkers of Risk of Parkinson Disease

NCT00775853
View directory record Official record
Conditions
Parkinson Disease, Autonomic Nervous System Diseases, Pure Autonomic Failure
Interventions
6-[18F]Fluorodopamine, 6-[18F]Fluorodopa, 13N-Ammonia
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 20, 2026, 5:40 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 20, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

Treatment of Supine Hypertension in Autonomic Failure (CPAP)

NCT03312556
View directory record Official record
Conditions
Supine Hypertension, Autonomic Failure
Interventions
continuous positive airway pressure (CPAP), Placebo
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 20, 2026, 5:40 AM EDT
Completed Phase 1Phase 2 Interventional

Automated Abdominal Binder for Orthostatic Hypotension

NCT03482297
View directory record Official record
Conditions
Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
Interventions
automated abdominal binder, Sham binder, Placebo, Midodrine
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 20, 2026, 5:40 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT04095793
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 20, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT03750552
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
ampreloxetine, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
23
States / cities
Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 20, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension

NCT03042988
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
Interventions
Heating pad, Sham control
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 20, 2026, 5:40 AM EDT
Completed No phase listed Observational

Variability Analysis as a Predictor of Liberation From Mechanical Ventilation

NCT01140750
View directory record Official record
Conditions
Mechanical Ventilation, Autonomic Nervous System Diseases
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2010 · Synced Sep 20, 2026, 5:40 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

NCT07775976
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions
COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
Device · Other
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Pasadena, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 20, 2026, 5:40 AM EDT
Terminated Phase 1 Interventional

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

NCT01292694
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
Losartan, Captopril, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 20, 2026, 5:40 AM EDT
Recruiting No phase listed Observational

Natural History Study of Synucleinopathies

NCT01799915
View directory record Official record
Conditions
Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension, Pure Autonomic Failure, REM Sleep Behavior Disorder, Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Shy-Drager Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 20, 2026, 5:40 AM EDT
Completed No phase listed Observational

Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension

NCT01316666
View directory record Official record
Conditions
Orthostatic Hypotension, Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 20, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Abdominal Compression in Orthostatic Hypotension

NCT01223391
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Abdominal binder, No abdominal binder
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 20, 2026, 5:40 AM EDT